235 related articles for article (PubMed ID: 17356951)
21. Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy.
Jamali FR; Darwiche SS; El-Kinge N; Tawil A; Soweid AM
Oncologist; 2007 Apr; 12(4):438-42. PubMed ID: 17470686
[TBL] [Abstract][Full Text] [Related]
22. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.
Bonvalot S; Eldweny H; Péchoux CL; Vanel D; Terrier P; Cavalcanti A; Robert C; Lassau N; Cesne AL
Ann Surg Oncol; 2006 Dec; 13(12):1596-603. PubMed ID: 16957966
[TBL] [Abstract][Full Text] [Related]
23. [Surgical treatment for patients with advanced gastrointestinal stromal tumor after targeted therapy].
Wang CM; Shi YQ; Ye YW; Fu H; Zhao GF; Zhou Y; DU CY; Dong RZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Mar; 12(2):155-8. PubMed ID: 19296251
[TBL] [Abstract][Full Text] [Related]
24. Imatinib in advanced gastrointestinal stromal tumour: when is 800 mg the correct dose?
Judson I
Curr Opin Oncol; 2008 Jul; 20(4):433-7. PubMed ID: 18525340
[TBL] [Abstract][Full Text] [Related]
25. [Expert consensus on surgical treatment for gastrointestinal stromal tumors].
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):947-8. PubMed ID: 18478940
[No Abstract] [Full Text] [Related]
26. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
27. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
Gold JS; van der Zwan SM; Gönen M; Maki RG; Singer S; Brennan MF; Antonescu CR; De Matteo RP
Ann Surg Oncol; 2007 Jan; 14(1):134-42. PubMed ID: 17080234
[TBL] [Abstract][Full Text] [Related]
28. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
29. Imatinib and inoperable or metastatic gastrointestinal stromal tumours. Longer follow-up confirms the overall survival benefit.
Prescrire Int; 2011 Mar; 20(114):61-3. PubMed ID: 21648223
[TBL] [Abstract][Full Text] [Related]
30. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
Rutkowski P; Nowecki Z; Nyckowski P; Dziewirski W; Grzesiakowska U; Nasierowska-Guttmejer A; Krawczyk M; Ruka W
J Surg Oncol; 2006 Mar; 93(4):304-11. PubMed ID: 16496358
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant and down-staging treatment with imatinib in gastrointestinal stromal tumors.
Nilsson B; Andersson A; Ahlman H
J Surg Oncol; 2008 Sep; 98(3):145-6. PubMed ID: 18452216
[No Abstract] [Full Text] [Related]
32. [An update of the surgical indications for gastrointestinal stromal tumors].
Bonvalot S
J Chir (Paris); 2008; 145 Suppl 3():6S8-11. PubMed ID: 19060842
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case.
Lo SS; Papachristou GI; Finkelstein SD; Conroy WP; Schraut WH; Ramanathan RK
Dis Colon Rectum; 2005 Jun; 48(6):1316-9. PubMed ID: 15793646
[TBL] [Abstract][Full Text] [Related]
34. [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear].
Ahlman H; Nilsson O; Nilsson B
Lakartidningen; 2009 Dec 9-21; 106(50-51):3424-9. PubMed ID: 20180446
[No Abstract] [Full Text] [Related]
35. Neoadjuvant treatment of rectal gastrointestinal stromal tumors with imatinib.
Turner J; Batus M; Leslie W; Coogan C; Saclarides TJ
Am Surg; 2010 Aug; 76(8):E110-2. PubMed ID: 21513625
[No Abstract] [Full Text] [Related]
36. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.
Gronchi A; Fiore M; Miselli F; Lagonigro MS; Coco P; Messina A; Pilotti S; Casali PG
Ann Surg; 2007 Mar; 245(3):341-6. PubMed ID: 17435538
[TBL] [Abstract][Full Text] [Related]
37. Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy.
Samelis GF; Ekmektzoglou KA; Zografos GC
Eur J Surg Oncol; 2007 Oct; 33(8):942-50. PubMed ID: 17196360
[TBL] [Abstract][Full Text] [Related]
38. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
39. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Kim HC; Kim KH; Yook JH; Kim BS; Kang YK
J Surg Oncol; 2008 Jul; 98(1):27-33. PubMed ID: 18452195
[TBL] [Abstract][Full Text] [Related]
40. [GIST: a clinical case as a model of surgical and pharmacological therapy of solid tumours].
D'Amato A; Pezzoli F; Caterino S; Cavallini M; Balducci G; Bocchetti T; Ziparo V
Chir Ital; 2005; 57(4):509-14. PubMed ID: 16060192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]